HK1016904A1 - Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis - Google Patents

Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis

Info

Publication number
HK1016904A1
HK1016904A1 HK99102262A HK99102262A HK1016904A1 HK 1016904 A1 HK1016904 A1 HK 1016904A1 HK 99102262 A HK99102262 A HK 99102262A HK 99102262 A HK99102262 A HK 99102262A HK 1016904 A1 HK1016904 A1 HK 1016904A1
Authority
HK
Hong Kong
Prior art keywords
ylethyl
naphth
tetrahydropyridine
trifluoromethylphenyl
lateral sclerosis
Prior art date
Application number
HK99102262A
Other languages
English (en)
Inventor
Patrice Douillet
Jacqueline Fournier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512635A external-priority patent/FR2740343B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of HK1016904A1 publication Critical patent/HK1016904A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
HK99102262A 1995-10-26 1999-05-24 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis HK1016904A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR9607336 1996-06-13
PCT/FR1996/001674 WO1997015304A1 (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Publications (1)

Publication Number Publication Date
HK1016904A1 true HK1016904A1 (en) 1999-11-12

Family

ID=26232287

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99102262A HK1016904A1 (en) 1995-10-26 1999-05-24 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis

Country Status (28)

Country Link
US (1) US6043251A (el)
EP (1) EP0866704B1 (el)
JP (1) JP3468526B2 (el)
KR (1) KR100472793B1 (el)
CN (1) CN1104241C (el)
AT (1) ATE200423T1 (el)
AU (1) AU719342B2 (el)
BR (1) BR9611124A (el)
CA (1) CA2235747C (el)
CY (1) CY2279B1 (el)
CZ (1) CZ293360B6 (el)
DE (1) DE69612510T2 (el)
DK (1) DK0866704T3 (el)
EE (1) EE04177B1 (el)
ES (1) ES2159362T3 (el)
GR (1) GR3036027T3 (el)
HK (1) HK1016904A1 (el)
HU (1) HU222039B1 (el)
IL (1) IL124091A (el)
IS (1) IS1961B (el)
NO (1) NO316256B1 (el)
NZ (1) NZ320355A (el)
PT (1) PT866704E (el)
SI (1) SI0866704T1 (el)
SK (1) SK284099B6 (el)
TR (1) TR199800717T2 (el)
UA (1) UA57004C2 (el)
WO (1) WO1997015304A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
IL162408A0 (en) * 2001-12-11 2005-11-20 Univ Virginia Use of pramipexole to treat amyotrophic lateral scelrosis
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007137071A2 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2008224844B2 (en) 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
DK3019167T3 (da) 2013-07-12 2021-03-15 Knopp Biosciences Llc Behandling af forhøjede niveauer af eosinophiler og/eller basophiler
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2672731A1 (fr) * 1991-02-07 1992-08-14 France Telecom Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
NO981856L (no) 1998-06-11
SI0866704T1 (en) 2001-08-31
CZ293360B6 (cs) 2004-04-14
EE04177B1 (et) 2003-12-15
HU222039B1 (hu) 2003-03-28
CY2279B1 (en) 2003-07-04
JPH11515012A (ja) 1999-12-21
CA2235747C (en) 2006-01-03
NO981856D0 (no) 1998-04-24
CZ129698A3 (cs) 1998-07-15
EP0866704A1 (fr) 1998-09-30
TR199800717T2 (xx) 1998-09-21
WO1997015304A1 (fr) 1997-05-01
IL124091A (en) 2003-10-31
AU719342B2 (en) 2000-05-04
IS1961B (is) 2004-11-15
HUP9802945A3 (en) 1999-05-28
CN1104241C (zh) 2003-04-02
US6043251A (en) 2000-03-28
KR100472793B1 (ko) 2005-06-16
ATE200423T1 (de) 2001-04-15
EE9800132A (et) 1998-10-15
EP0866704B1 (fr) 2001-04-11
SK52698A3 (en) 1998-09-09
BR9611124A (pt) 1999-05-11
GR3036027T3 (en) 2001-09-28
DK0866704T3 (da) 2001-07-16
CA2235747A1 (en) 1997-05-01
PT866704E (pt) 2001-07-31
CN1202826A (zh) 1998-12-23
UA57004C2 (uk) 2003-06-16
NZ320355A (en) 2000-03-27
NO316256B1 (no) 2004-01-05
JP3468526B2 (ja) 2003-11-17
DE69612510D1 (de) 2001-05-17
HUP9802945A2 (hu) 1999-04-28
DE69612510T2 (de) 2001-11-22
SK284099B6 (sk) 2004-09-08
ES2159362T3 (es) 2001-10-01
IS4722A (is) 1998-04-21
KR19990067057A (ko) 1999-08-16
AU7308496A (en) 1997-05-15
MX9803271A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
SI0866704T1 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
GR3020975T3 (en) Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes.
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
TW261532B (el)
DE69636393D1 (de) Montirelin zur verhinderung der schlafapnoe
IL110006A0 (en) New use of ropivacaine
AU6991696A (en) 3-beta-aminoazabicyclo-octane or -nonane naphthamide derivatives as antipsychotic agents
GB9507883D0 (en) Compounds
GR3036205T3 (en) Use of phosphorus derivatives of alkaloids for treating endocrinopathies
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
AU1195497A (en) Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081025